Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

medreg s.r.o. - imipenem anhydrous cilastatin - pdr for soln for infusion - 500/500 milligram

Malta - inglise - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - imipenem, cilastatin - powder for solution for infusion - imipenem 500 mg cilastatin 500 mg - antibacterials for systemic use

Malta - inglise - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - imipenem, cilastatin - powder for solution for infusion - imipenem 500 mg cilastatin 500 mg - antibacterials for systemic use

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

merck sharp & dohme llc - imipenem anhydrous (unii: q20im7he75) (imipenem anhydrous - unii:q20im7he75), cilastatin (unii: 141a6amn38) (cilastatin - unii:141a6amn38), relebactam anhydrous (unii: 1oqf7tt3pf) (relebactam anhydrous - unii:1oqf7tt3pf) - recarbrio™ is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: acinetobacter calcoaceticus-baumannii complex, enterobacter cloacae , escherichia coli , haemophilus influenzae , klebsiella aerogenes, klebsiella oxytoca, klebsiella pneumoniae, pseudomonas aeruginosa, and serratia marcescens. recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cuti), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: enterobacter cloacae , escherichia coli , klebsiella aerogenes, klebsiella pneumoniae, and pseudomonas aeruginosa . approval of this indication is based on limited clinical safety and efficacy data for recarbrio [see clinical studies (14.2)] . recarbrio is indicated in patients

Armeenia - inglise - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - imipenem (imipenem monohydrate), cilastatin (cilastatin sodium) - powder for solution for infusion - 500mg+500mg

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - imipenem; cilastatin sodium -

Singapur - inglise - HSA (Health Sciences Authority)

hospira singapore pte. ltd. - cilastatin sodium 265.34 mg eqv cilastatin - injection, powder, for solution - 250mg/vial

Singapur - inglise - HSA (Health Sciences Authority)

hospira singapore pte. ltd. - cilastatin sodium 530.67 mg eqv cilastatin - injection, powder, for solution - 500 mg/vial

Kenya - inglise - Pharmacy and Poisons Board

syner-med pharmaceuticals (k) ltd icd road, off mombasa road, nairobi - 52096-00200 - imipenem and cilastatin sodium - injection - imipenem 500mg and cilastatin 500mg/vial - beta-lactamantibacterials: carbapenems

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

genentech, inc. - ganciclovir sodium (unii: 02l083w284) (ganciclovir - unii:p9g3ckz4p5) - ganciclovir 500 mg in 10 ml - cytovene-iv is indicated for the treatment of cytomegalovirus (cmv) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)] . cytovene-iv is indicated for the prevention of cmv disease in adult transplant recipients at risk for cmv disease [see clinical studies (14.2)]. cytovene-iv is contraindicated in patients who have experienced a clinically significant hypersensitivity reaction (e.g., anaphylaxis) to ganciclovir, valganciclovir, or any component of the formulation. risk summary in animal studies, ganciclovir caused maternal and fetal toxicity and embryo-fetal mortality in pregnant mice and rabbits as well as teratogenicity in rabbits at exposures two times the exposure at the recommended human dose (rhd) [see data] . although placental transfer of ganciclovir has been shown to occur based on ex vivo experiments with human placenta and in at least one case report in a pregnant woman, no adequate human data are available